JAK Inhibitor vs Biologic for Rheumatoid Arthritis

When methotrexate alone stops controlling your rheumatoid arthritis, your doctor will likely recommend either a biologic or a JAK inhibitor. Both are effective for moderate-to-severe RA — but they work differently, carry different safety tradeoffs, and suit different patients. The choice is not one-size-fits-all. Your age, other health conditions, how you prefer to take medication, and whether you have already tried a biologic all factor into it.

This explainer draws on research by five rheumatologists listed in the Convene directory whose published work directly informs this comparison. Alan Kivitz at UPMC Altoona co-authored the ORAL Strategy trial — the landmark head-to-head study of tofacitinib versus adalimumab — as well as the SELECT-NEXT upadacitinib trial and a filgotinib versus adalimumab phase III trial. Charles Ludivico at St. Luke's participated in the RA-BEACON baricitinib trial and the SUMMACTA tocilizumab trials. Kenneth Saag at UAB co-authored the 2015 ACR RA treatment guidelines and the 2019 EULAR update. Jeffrey Curtis at UAB also co-authored both ACR guidelines and has published on comparative effectiveness of RA therapies. Jeffrey Sparks at Brigham and Women's Hospital authored a comprehensive RA review in Annals of Internal Medicine.

What biologics are and how they work

Biologics are injectable proteins — usually given by subcutaneous shot or intravenous infusion — that block a specific molecule involved in RA inflammation. The most commonly used are TNF inhibitors, which block tumor necrosis factor, a cytokine that drives joint swelling and damage. Examples include adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), and golimumab (Simponi). Other biologics target different pathways: abatacept (Orencia) interrupts T-cell activation; rituximab (Rituxan) depletes B cells; and IL-6 inhibitors like tocilizumab (Actemra) and sarilumab (Kevzara) block a different inflammatory cytokine.

A 2013 randomized trial published in Annals of the Rheumatic Diseases compared the subcutaneous and intravenous forms of tocilizumab head-to-head in patients with moderate-to-severe RA. The subcutaneous formulation showed comparable efficacy to the intravenous form at two years, and extended follow-up confirmed that [4]. This matters because patients who receive biologics by injection at home avoid infusion center visits, though some still prefer the office setting for monitoring.

What JAK inhibitors are and how they work

JAK inhibitors — sometimes called jakinibs or targeted synthetic DMARDs (tsDMARDs) — are oral pills that block enzymes inside immune cells called Janus kinases (JAK1, JAK2, JAK3, or TYK2). These enzymes carry inflammatory signals from cell surface receptors into the nucleus. Blocking them interrupts multiple inflammatory pathways at once rather than targeting a single cytokine the way biologics do.

Approved JAK inhibitors for RA in the United States include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq). Filgotinib (Jyseleca) is approved in Europe but not the US. Because they are oral, they do not require injections or infusions.

What the head-to-head trials showed

The most informative comparison of a JAK inhibitor against a biologic came from the ORAL Strategy trial, published in The Lancet in 2017 [1]. This phase 3b/4 randomized controlled trial put tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate head to head in 1,146 patients with active RA and an inadequate response to methotrexate. After one year, tofacitinib combined with methotrexate was found to be non-inferior to adalimumab plus methotrexate on the primary endpoint of ACR50 response. Tofacitinib monotherapy was not non-inferior to adalimumab with methotrexate, though the absolute differences were small.

Filgotinib versus adalimumab was tested in a phase III randomized trial published in Annals of the Rheumatic Diseases in 2021 [5]. Filgotinib at 200 mg demonstrated non-inferiority to adalimumab on ACR20 response at 24 weeks in patients with an inadequate response to methotrexate. This is the second direct JAK-versus-biologic head-to-head from a large phase III program.

For patients who have already tried and failed a biologic, baricitinib provides a different question: can a JAK inhibitor work after TNF inhibitors have not? The RA-BEACON trial, published in New England Journal of Medicine in 2016, enrolled patients with active RA who had inadequate response to one or more biologic DMARDs — a population that is often harder to treat [3]. Baricitinib 4 mg once daily showed significant improvement in disease activity scores and physical function compared to placebo at 12 weeks. This established that JAK inhibitors can be effective even in biologic-experienced patients.

At a glance

What the guidelines say

The 2015 ACR RA treatment guidelines, co-authored by Kenneth Saag and Jeffrey Curtis and published in Arthritis & Rheumatology, were among the first to formally position tofacitinib as an alternative to biologics in patients with moderate-to-high disease activity after methotrexate failure [7]. Tofacitinib was recommended as a conditional alternative to biologics for most patients in that scenario. The guidelines specify that treatment decisions should be individualized through shared decision-making, accounting for patient values and comorbidities.

The 2019 EULAR recommendations for RA management, which Kenneth Saag co-authored and which were published in Annals of the Rheumatic Diseases, updated this guidance as more JAK inhibitor trial data accumulated [6]. The EULAR panel recommends that after conventional DMARDs fail, biologics and JAK inhibitors have similar priority placement — neither category is preferred over the other on efficacy grounds. Specific patient factors, including prior cancer history, cardiovascular risk, and thrombosis risk, should guide the choice.

A comprehensive RA review by Jeffrey Sparks, published in Annals of Internal Medicine in 2018, provides context on why treatment selection beyond methotrexate matters: RA is a systemic inflammatory disease that raises the risk of serious infections, cardiovascular disease, osteoporosis, respiratory disease, and excess mortality [8]. Sustained disease control — achieved through whatever DMARD combination works for the patient — is the goal, because active inflammation drives those downstream risks.

Safety differences that matter for some patients

Both biologics and JAK inhibitors increase infection risk, particularly serious bacterial infections and reactivation of latent tuberculosis. Before starting either, your doctor will screen for latent TB and review your vaccination history.

Where the two classes diverge in safety is in a few specific areas.

In 2021, the FDA required all approved JAK inhibitors to carry an updated black box warning based on a large safety study (ORAL Surveillance) that found patients taking tofacitinib who were over 50 and had at least one cardiovascular risk factor had higher rates of major cardiovascular events, blood clots, and all-cause mortality compared to those taking TNF inhibitors. The FDA has since extended this caution to all JAK inhibitors, even though the evidence base varies by drug. For patients over 50 with cardiovascular disease, prior clots, or active smoking, rheumatologists often favor biologics — especially TNF inhibitors — over JAK inhibitors as a first choice.

Biologics carry their own class-specific concerns. TNF inhibitors can reactivate latent tuberculosis and are contraindicated in certain serious infections. They also carry a black box warning for lymphoma, though the absolute risk increase in RA patients is debated because RA itself raises lymphoma risk. Rituximab, which depletes B cells, requires infusion center visits and can cause prolonged immunosuppression. IL-6 inhibitors like tocilizumab and sarilumab can cause low white blood cell counts and elevated liver enzymes that need monitoring.

For patients with prior serious infections, demyelinating disease, or heart failure, certain biologics may be contraindicated. A rheumatologist's job is to match the risk profile of the treatment to the risk profile of the patient.

When each option tends to be preferred

JAK inhibitors are often a practical choice when:

• You strongly prefer oral medication over injections or infusions
• Refrigeration or travel is a logistical challenge
• You have already tried and failed a biologic and your doctor wants to try a different mechanism
• Insurance formulary coverage favors a JAK inhibitor in your plan

Biologics tend to be preferred when:

• You are over 50 with significant cardiovascular risk factors, a history of blood clots, or active smoking
• You have a history of certain cancers (some oncologists prefer to avoid JAK inhibitors in these patients)
• You are pregnant or planning pregnancy (biologics like certolizumab pegol have more safety data in pregnancy than JAK inhibitors)
• Your rheumatologist wants to use a TNF inhibitor first because they have the longest track record in RA

Neither category has a clear efficacy edge. The ORAL Strategy trial showed non-inferiority of tofacitinib plus methotrexate versus adalimumab plus methotrexate [1], and the filgotinib trial showed similar non-inferiority against adalimumab [5]. In practice, rheumatologists often start with a TNF inhibitor because of decades of safety data, then consider a JAK inhibitor or a different biologic class if the first agent fails.

Questions to ask your rheumatologist

• Given my cardiovascular history, do you recommend a biologic or a JAK inhibitor as my first add-on therapy?
• If I try a TNF inhibitor and it does not work well enough, what would you recommend next?
• What monitoring do I need while taking a JAK inhibitor (blood counts, lipids, liver enzymes)?
• Are there biosimilars available for the biologic you are recommending, and would those lower my out-of-pocket cost?
• How quickly should I expect to feel a difference, and what does a good response look like at three months?

The bottom line

JAK inhibitors and biologics are both effective options for RA that has not responded adequately to methotrexate. Head-to-head trials, including the ORAL Strategy trial comparing tofacitinib to adalimumab and the filgotinib versus adalimumab trial, show broadly similar disease control for most patients [1][5]. The main practical differences are route of administration (oral versus injectable) and a safety distinction that matters for certain patients: JAK inhibitors carry an additional caution about cardiovascular events and clotting risk in patients over 50 with cardiovascular risk factors, which can make biologics the better starting point for that group. For patients who have already tried and failed a biologic, JAK inhibitors like baricitinib can still work well [3]. The 2015 ACR guideline and the 2019 EULAR recommendations both position the two classes as roughly equivalent alternatives after methotrexate — the right choice depends on your specific health history, preferences, and what your rheumatologist knows about your overall risk profile [6][7].